Acute exacerbations of progressive-fibrosing interstitial lung diseases
Martin Kolb(McMaster University), Shane Shapera(University Health Network), Yasunari Miyazaki(Tokyo Medical and Dental University), Benjamin Bondue(Université Libre de Bruxelles), John T. Huggins(Medical University of South Carolina), Jin Woo Song(Ulsan College), María L. Padilla(Icahn School of Medicine at Mount Sinai), Alberto Pesci(University of Milano-Bicocca), Jesse Roman(Thomas Jefferson University), Nitin Bhatt(The Ohio State University Wexner Medical Center), Justin M. Oldham(Michigan Medicine)
Cited by 180
Related Papers
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases
|New England Journal of Medicine|2019|2.3k
Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals
|Annals of the American Thoracic Society|2018|723
Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial
|The Lancet Respiratory Medicine|2020|558
<i>TOLLIP</i> , <i>MUC5B</i> , and the Response to <i>N</i> -Acetylcysteine among Individuals with Idiopathic Pulmonary Fibrosis
|American Journal of Respiratory and Critical Care Medicine|2015|358
What's in a name? That which we call IPF, by any other name would act the same
|European Respiratory Journal|2018|352